Skip to main content
Have a personal or library account? Click to login
Experimental central composite design-based dispersive liquid-liquid microextraction for HPLC-DAD determination of diazinon in human urine samples: method development and validation Cover

Experimental central composite design-based dispersive liquid-liquid microextraction for HPLC-DAD determination of diazinon in human urine samples: method development and validation

Open Access
|Apr 2020

Figures & Tables

Table 1

Variables and their levels for experimental design

SymbolLevel 3Level 2Level 1Factor
Amethanolacetonitriltype of disperser solvent
B100sonication duration (minute)
Cdichloromethanechloroformtoluenetype of extraction solvent
D600300100volume of extraction solvent (μL)
E10005000volume of disperser solvent (μL)
F531surfactant concentration (% w/v)
G531salt concentration (% w/v)
H1074pH
Table 2

Analysis of variance for the proposed model

SourceSum of SquaresdfMean squareF valuep-value* Prob.> F
Model6195.8914442.5641.690.0053
A2223.7812223.77206.490.0007
B72.231172.316.810.0797
C726.082363.0434.20.0086
D862243140.60.0067
E229.052114.5210.790.0426
F1029.912514.9548.510.0052
G915.542457.7743.120.0062
H137.22268.616.460.0817
Residual31.85310.62
Correction Total6227.77417

* all p-values are statistically significant

Table 3

Experimental ranges and levels of independent variables for the central composite design

α-1-01+α+
MethanolμLA2004006008001000
NaCl%B01234
SLS%C01234
TolueneμLD225300375450525

[i] SLS – sodium lauryl sulphate

Table 4

Experimental conditions according to the central composite design and observed response values

Experiment No.Methanol volume (μL)NaCl conc. (%w/v)SLS conc. (%w/v)Toluene volume (μL)Actual recoveryPredicted recovery
18003.003.00300.0043.7040.72
28003.001.00300.0020.1021.55
38001.003.00450.0082.0080.49
44003.001.00450.0069.2768.99
58001.001.00450.0043.5243.50
64001.003.00300.0046.343.06
74003.003.00450.0063.0061.23
84001.001.00300.0031.8032.99
92002.002.00375.0063.0064.14
1010002.002.00375.0053.5054.13
116000.002.00375.0067.5067.14
126004.002.00375.0029.0028.64
136002.000.00375.0018.0215.94
146002.004.00375.0041.3345.18
156002.002.00225.0042.0042.88
166002.002.00525.0073.6074.48
176002.002.00375.0048.0047.89
186002.002.00375.0046.0047.89
196002.002.00375.0049.0047.89
206002.002.00375.0050.0047.89
216002.002.00375.0044.0047.89

[i] SLS – sodium lauryl sulphate

Figure 1

Probability plot of the effects

Table 5

Analysis of variance for central composite design

SourceSum of squaresdfMean squareF valuep-value* Prob. > F
Model840.21176.3763.10<0.0001
A16.28116.2813.450.0052
B112.891112.8993.28<0.0001
C142.351142.35117.63<0.0001
D70.52170.5258.27<0.0001
AB27.88127.8823.040.0010
AC53.21153.2143.97<0.0001
AD44.91144.9137.110.0002
BC19.36119.3616.000.0031
A^231.00131.0025.620.0007
C^284.41184.4169.75<0.0001
D^226.72126.7222.080.0011
Residual10.8991.21
Lack of Fit7.3751.471.670.3196
Pure Error3.5340.88
Cor Total850.9120

* all p-values are statistically significant

Figure 2

Surface plots showing the effects of variables with the highest impact on the recovery of the method

(A) The effect of the volume of toluene and methanol; (B) the effect of the volume of methanol and the sodium lauryl sulphate (SLS) concentration; (C) the effect of methanol volume and the sodium chloride (NaCl) concentration

Table 6

Method precision and accuracy (intra-day: n=5; inter-day: n=5 series per day, 3 days).

Mean±SDCV (%)Recovery±SD (%)Mean±SDCV (%)Recovery±SD (%)
0.50.46±0.047.492.1±1.00.48±0.036.995.6±1.0
10.76±0.023.376.0±2.00.75±0.011.275.0±1.1
32.33±0.094.077.4±0.92.31±0.114.977.1±1.4
Figure 3

Specificity of the proposed method for the analysis of diazinon in urine sample

Chromatogram A: blank urine; Chromatogram B: urine spiked with: 1 – tramadol, 2 – azinphos-ethyl, 3 – diazinon, 4 – pirimiphosmethyl, and 5 – chlorpyrifos

Table 7

Comparison of the proposed DLLME-HPLC-DAD with other analytical methods for determination of diazinon in biological samples

MethodMatrixLOD (μg/mL)Correlation coefficient (R2)Recovery (%)Ref. No.
SPE-GC-MSwhole blood0.150.998178–8715
SPE-HPLC-DADplasma0.150.99877.7–86.317
LLE-HPLC-DADwhole blood, serum, urine0.780.999697.4–99.01 (for blood and serum)
101.1–101.4 (for urine)
16
mini-QuEChERS-LC-MS-MSwhole blood, gastric content0.10.9580–10018
MEPS-GC-MS-MSwhole blood0.50.9961–7726
DBS-GC-MS-MSwhole blood0.050.9984.56–5.1127
DLLME-HPLC-DADurine0.150.99375.0–95.6this study

[i] SPE-GC-MS – solid-phase extraction and gas chromatography/mass spectrometry; SPE-HPLC-DAD – solid-phase extraction and high-performance liquid chromatography (HPLC) with diode array detector (DAD); LLE-HPLC-DAD – liquid-liquid extraction and high-performance liquid chromatography (HPLC) with diode array detector; mini-QuEChERS-LC-MS-MS – modified quick, easy, cheap, effective, rugged and safe (QuEChERS) method – liquid chromatography with tandem mass spectrometry; MEPS-GC-MS-MS – microextraction by packed sorbent (MEPS) – gas chromatography-tandem mass spectrometry; DBS-GC-MS-MS – dried blood spot (DBS) – gas chromatography coupled to tandem mass spectrometry; DLLME-HPLC-DAD – dispersive liquid- liquid phase microextraction-high performance liquid chromatography with diode array detector

DOI: https://doi.org/10.2478/aiht-2020-71-3292 | Journal eISSN: 1848-6312 (formerly 0004-1254) | Journal ISSN: 0004-1254
Language: English
Page range: 48 - 55
Submitted on: May 1, 2019
Accepted on: Feb 1, 2020
Published on: Apr 9, 2020
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services

© 2020 Reza Mohammadzaheri, Mehdi Ansari Dogaheh, Maryam Kazemipour, Kambiz Soltaninejad, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.